Company Overview
Bio Green Med Solution, Inc. operates primarily through the distribution, trading, and installation of protective and fire safety materials, equipment, and fire protection systems, while simultaneously engaging in the research and development of pharmaceuticals. The company is positioned within the Healthcare sector, specifically classified under the Biotechnology industry, which implies a focus on innovative medical solutions alongside established safety infrastructure services. The firm's scale is defined by a market capitalization that is not publicly disclosed in the available data, an annual revenue of $81,000, and an employee count listed as N/A. These financial figures indicate that the company operates on a very small revenue base relative to typical biotechnology peers, suggesting a micro-cap status where revenue generation is currently limited to specific niche operations rather than broad commercialization.
Financial Health
The company reports a trailing twelve-month revenue of $81,000, yet it generated a net income of $-6,974,000 and an EBITDA of $-9,171,000 during the same period. The substantial gap between the minimal revenue of $81,000 and the massive negative net income of $-6,974,000 reveals a highly volatile cost structure where expenses, likely driven by research and development or operational overhead, vastly exceed all income generated. Free cash flow stands at $-9,983,125, indicating that the company is burning cash rapidly and lacks the internal financial flexibility to fund operations or growth without external capital injections. Analyzing the margin profile, the gross margin is 0.0%, the operating margin is -1224.7%, and the profit margin is 0.0%, which collectively indicate that the company is not covering its direct costs of goods sold or operating expenses with its current sales volume. On the balance sheet, the company holds $3.84M in cash against only $5,000 in debt, resulting in a debt-to-equity ratio of 0.07, which suggests the balance sheet is heavily weighted toward liquidity rather than leverage, despite the cash being insufficient to cover the operational burn rate. The current ratio of 6.43 indicates a strong position regarding short-term liquidity, as the company possesses over six times the current assets necessary to meet its immediate liabilities. However, the return on equity is -177.6% and the return on assets is -84.7%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital deployed in assets.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the negative earnings and lack of profitability, which implies that traditional earnings-based valuation methods cannot be applied to assess the company's future earnings trajectory or growth expectations. The price-to-book ratio is 0.71, indicating that the market is valuing the company at less than its book value, a situation often seen in distressed or pre-revenue biotechnology firms where the market does not assign a premium to the underlying assets. Price-to-sales and EV/EBITDA metrics are partially unavailable or negative, with a price-to-sales ratio listed as N/A and an EV/EBITDA of -0.17, suggesting that alternative valuation multiples are not meaningful given the negative earnings and minimal revenue generation. The stock has exhibited significant price volatility, trading between a 52-week high of $14.00 and a 52-week low of $1.44. Without a specific current price provided in the source data to calculate a precise percentage, the trading range itself highlights the extreme speculative nature of the security, with the stock capable of trading at a premium or discount far exceeding typical fundamental valuations. The beta value is -0.48, which is an anomalous figure indicating an inverse correlation to the broader market or a statistical artifact, suggesting that the stock's price movements do not follow standard market volatility patterns and may move independently of general market trends.
Growth & Income
The company reports a revenue growth year-over-year of 710.0%, while earnings growth is listed as N/A due to the persistent negative net income. The disparity between the explosive revenue growth and the inability to generate positive earnings growth implies that the new revenue streams are being overwhelmed by high fixed costs or R&D expenditures, preventing profitability. Regarding income, the dividend yield is reported as 54.5%, yet the payout ratio is N/A, which creates a critical disconnect since a sustainable payout ratio cannot be calculated with negative earnings. This high dividend yield in the context of negative earnings and a lack of profit suggests the dividend is not funded by current earnings but likely by the cash reserves or debt issuance, making it unsustainable given the current financial trajectory. The overall growth and income profile is characterized by high revenue expansion that has not yet translated into profitability, coupled with a dividend structure that does not reflect traditional earnings-based sustainability.